FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 163.924

Change

+3.01 (+1.87)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-02 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.89 (+1.38%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

+0.95 (+1.48%)

USD 2.50B
FXH First Trust Health Care AlphaD..

+1.20 (+1.21%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

+1.49 (+1.89%)

USD 0.16B
IDNA iShares Genomics Immunology an..

+0.39 (+1.89%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

+1.39 (+1.45%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.27 (+0.90%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.74 (+2.77%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-0.42 (-0.71%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.47 (+2.46%)

USD 0.01B

ETFs Containing FBT

FHM:CA 0.00 % 0.78 %

N/A

N/A
FBT:CA First Trust NYSE Arca Bio.. 0.00 % 0.00 %

-0.12 (-0.43%)

CAD 1.83M

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.38% 52% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.38% 52% F 50% F
Trailing 12 Months  
Capital Gain 10.61% 100% F 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.61% 100% F 69% C-
Trailing 5 Years  
Capital Gain 11.26% 38% F 38% F
Dividend Return 1.50% 37% F 3% F
Total Return 12.77% 38% F 27% F
Average Annual (5 Year Horizon)  
Capital Gain 0.77% 38% F 39% F
Dividend Return 1.10% 38% F 29% F
Total Return 0.33% 42% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 11.47% 81% B- 75% C
Risk Adjusted Return 9.55% 43% F 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.